Gestala Raises $21.6M for Ultrasound Brain-Computer Interface
▼ Summary
– Gestala, a new Chinese startup, has raised $21.6 million just two months after its founding, marking China’s largest early-stage brain-computer interface (BCI) funding round, which was heavily oversubscribed.
– The company is developing a non-invasive BCI technology using focused ultrasound, which can access deep brain circuits without surgery, unlike implant-based systems.
– Its primary clinical focus is chronic pain management, with research also exploring applications in mental health, stroke rehabilitation, and neurodegenerative diseases like Alzheimer’s.
– Gestala aims to leverage China’s manufacturing ecosystem and lower clinical trial costs as competitive advantages and is building an ‘Ultrasound Brain Bank’ dataset to train AI models for brain signal decoding.
– The funding will support R&D, team expansion, and establishing a manufacturing facility, with a first-generation prototype targeted for completion by the end of 2026.
A new Chinese startup has secured a landmark investment to advance a novel, non-invasive approach to brain-computer interface technology. Gestala has raised $21.6 million in a heavily oversubscribed seed round, marking the largest early-stage financing deal in China’s burgeoning BCI sector. Founded by Phoenix Peng, who also started the implantable BCI company NeuroXess, Gestala is pursuing a radically different path by eliminating the need for surgery entirely.
The company’s core innovation is a BCI system powered by focused ultrasound. This technology uses sound waves to penetrate the skull safely, allowing it to both monitor and precisely influence neural activity in deep brain regions without a single incision. Peng argues that the daunting requirement for brain surgery is the primary obstacle preventing widespread BCI adoption, and his firm’s ultrasound-based method directly tackles this challenge.
The funding round was co-led by Guosheng Capital and Dalton Venture, with several other prominent firms participating. Investor enthusiasm was exceptionally high, with total commitments exceeding $58 million, making the final allocation more than two and a half times oversubscribed. This strong market vote of confidence values the two-month-old startup between $100 million and $200 million.
Gestala’s primary clinical focus is on chronic pain management, a condition affecting millions globally where early research suggests ultrasound neuromodulation could offer significant relief. The company’s research pipeline, however, extends much further. It is actively investigating applications for several mental health conditions, including depression and PTSD, alongside stroke rehabilitation. Longer-term ambitions target neurodegenerative diseases like Alzheimer’s and Parkinson’s.
While several U.S. companies, such as Merge Labs, are also developing ultrasound BCI technology, Peng believes Gestala holds a unique position as China’s first entrant in this niche. He points to structural advantages in China’s integrated manufacturing ecosystem and significantly lower clinical trial costs as key factors that could accelerate the company’s path from prototype to product. Clinical studies in China can cost a fraction of equivalent trials in the West, and Gestala is already collaborating with major Chinese hospitals to advance its research.
Beyond therapeutic applications, the startup is compiling a large clinical dataset termed an ‘Ultrasound Brain Bank’. This repository is designed to train advanced AI algorithms to interpret brain signals, with the future goal of aiding in neurological diagnostics. Peng envisions a collaborative global landscape for deep-tech, where China’s manufacturing and clinical scale complements the premier scientific talent found in the United States, despite current geopolitical friction.
The substantial investment in Gestala reflects a wider surge of capital into brain-computer interfaces worldwide. This trend is exemplified by recent large rounds for companies like Neuralink and Merge Labs. Gestala will use its new capital to expand its research and development efforts, grow its team, and establish a production facility in China. The company aims to complete its first-generation prototype before the close of 2026.
(Source: The Next Web)
